The U.S. Army will continue NGC2 experimentation and prototyping via an OTA agreement to Team Anduril on behalf of PEO C3N.

The U.S. Marine Corps will field smart scopes to help shoot down moving targets, such as drones, in the coming months.

The Pentagon is looking to accelerate development of the ultra-fast weapons in response to recent testing of hypersonics by Russia and China.

Bristol Myers Squibb has expanded its push into radiopharma by licensing a prostate cancer therapy developed by Philochem for $350m upfront.